FDA RECALLS & COURT ACTIONS: April 1, 1992
Executive Summary
CLASS III -- BENZTROPINE MESYLATE TABLETS 0.5 mg, repacked into unit dose containers. Recall number: D-280-2. Lot numbers: 2547-018 9/92, 2547-019 10/92, 2547-020 10/92. Manufacturer: Sidmak Laboratories, Inc., East Hanover, New Jersey. Recalled by: Vangard Labs, Inc., Glasgow, Kentucky (repacker). Firm- initiated recall ongoing. Distribution: Nationwide. Firm estimates 6,800 tablets remain on the market. Reason: Product does not meet USP content uniformity specifications. CLASS III -- CALAMINE LOTION In 4 and 8 ounce bottles, an OTC topical drug. Recall number: D-278- 2. All lots in date. Manufacturer: Barre-National, Inc., Baltimore, Maryland. Recalled by: Manufacturer, by letter Jan. 30, 1992. Firm- initiated recall ongoing. Distribution: Nationwide, Bahamas, Guam. 494,798 units were distributed; firm estimates 9,364 units remain on the market. Reason: Product does not meet stability specifications. CLASS III -- PROMETH WITH CODEINE In 4 and 16 ounce bottles, a Rx drug indicated for the temporary relief of cough and upper respiratory symptoms associated with allergies or the common cold. Recall number: D-279-2. Lot number 03659 EXP 06/92. Manufacturer: Barre-National, Inc., Baltimore, Maryland. Recalled by: Manufacturer, by letter Jan. 30, 1992. Firm- initiated recall ongoing. Distribution: Nationwide. 128,861 units were distributed; firm estimates 24 units remain on the market. Reason: Subpotency of promethazine ingredient.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth